Bone Mass Continues to Increase at the Hip After Parathyroid Hormone Treatment Is Discontinued in Glucocorticoid‐Induced Osteoporosis: Results of a Randomized Controlled Clinical Trial

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Bone and Mineral Research

• Publication date

  2000-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1359/jbmr.2000.15.5.944PMID 10804025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol

  2005cited by this paper
• Glucocorticoid osteoporosis.

  2002cited by this paper
• Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.

  1999cited by this paper
• A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment

  1998cited by this paper
• Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

  1998cited by this paper
• Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

  1998cited by this paper
• Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.

  1998cited by this paper
• Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.

  1997cited by this paper
• Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

  1997cited by this paper
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis

  1996cited by this paper
• Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures

  1995cited by this paper
• Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids.

  1994cited by this paper
• Corticosteroid-induced osteoporosis.

  1993cited by this paper
• Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

  1993cited by this paper
• Estrogen and progesterone replacement therapy reduces glucocorticoid‐induced bone loss

  1992cited by this paper
• hPTH 1–34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses

  1991cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management.

  1990cited by this paper
• Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25‐dihydroxyvitamin D

  1986cited by this paper
• Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis

  1983cited by this paper
• A Bioassay for Parathyroid Hormone using Chicks

  1973cited by this paper
• A chick bioassay for parathyroid hormone.

  1973cited by this paper
• An evaluation of antibodies and clinical resistance to salmon calcitonin.

  1972cited by this paper

• Therapeutic Management of Glucocorticoid-Induced Osteoporosis with a Focus on Older Adults: A Narrative Review

  2025influential citation
• Successful treatment of a challenging periprosthetic femoral fracture on a premenopausal patient with a long history of immunosuppression

  2024cites this paper
• Acupuncture in Treating Osteopenia: A Multicenter, Randomized, Controlled Clinical Trial

  2024cites this paper
• Transitory Activation and Improved Transition from Erosion to Formation within Intracortical Bone Remodeling in Hypoparathyroid Patients Treated with rhPTH(1–84)

  2023cites this paper
• [The recombinant human parathyroid hormone, teriparatide as an alternative remedy for the medication-related osteonecrosis of the jaw].

  2023cites this paper
• Argentine Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men Aged 50 Years and Older

  2023cites this paper
• Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview

  2023cites this paper
• Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy.

  2022cites this paper
• Teriparatide and abaloparatide treatment for osteoporosis

  2021cites this paper
• Osteoporosis in premenopausal women, pregnancy, and lactation

  2021cites this paper
• Glucocorticoid-induced osteoporosis and Cushing’s syndrome

  2021cites this paper
• Osteoporosis in Premenopausal Women

  2020cites this paper
• Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.

  2020cites this paper
• Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications.

  2020cites this paper
• An Overview of Glucocorticoid Induced Osteoporosis-Endotext-NCBI Bookshelf

  2019cites this paper
• Metabolic Bone Disease in Gastrointestinal Disorders

  2019cites this paper
• Effects of teriparatide on bone in autochthonous transgenic model mice for diabetes mellitus (Akita mice)

  2019cites this paper
• Hip Fracture Discrimination Based on Statistical Multi-parametric Modeling (SMPM)

  2019cites this paper
• Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.

  2019cites this paper
• Parathyroid hormone and abaloparatide treatment for osteoporosis

  2018cites this paper
• Effects of human parathyroid hormone on bone morphogenetic protein signal pathway following spinal fusion in diabetic rats.

  2017cites this paper
• For the first fracture to be the last

  2016cites this paper
• Glucocorticoid-induced Osteoporosis.

  2016cites this paper
• Para que a primeira fratura seja a última

  2016cites this paper
• Glucocorticoid-induced osteoporosis

  2015cites this paper
• Parathyroid Hormone and Glucocorticoid-induced Osteoporosis

  2015cites this paper
• Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.

  2015cites this paper
• Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength

  2015cites this paper
• Parathyroid Hormone as Monotherapy for the Treatment of Osteoporosis

  2015cites this paper
• Bone forming agents for the management of osteoporosis.

  2014cites this paper
• Chapter 49 – Glucocorticoid-Induced Osteoporosis

  2013cites this paper
• Osteoporosis in Premenopausal Women

  2013cites this paper
• Recombinant hormones in osteoporosis

  2013cites this paper
• Parathyroid hormone (1-34) counteracts the suppression of interleukin-11 expression by glucocorticoid in murine osteoblasts: a possible mechanism for stimulating osteoblast differentiation against glucocorticoid excess.

  2013influential citation
• The Role of Osteocyte Apoptosis on Osteoclast Precursor Recruitment

  2013cites this paper
• Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.

  2013cites this paper
• Parathyroid Hormone: Anabolic Treatment of Osteoporosis

  2013cites this paper
• Chapter 85 – Parathyroid Hormone Treatment for Osteoporosis

  2013cites this paper
• Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives.

  2013cites this paper
• The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis.

  2012cites this paper
• Teriparatide

  2012cites this paper
• Parathyroid Hormone as an Anabolic Skeletal Therapy

  2012cites this paper
• Corticosteroid-Induced Osteoporosis

  2012cites this paper
• Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications

  2012cites this paper
• Parathyroid hormone analogues in the treatment of osteoporosis

  2011cites this paper
• Glucocorticoid dose determines osteocyte cell fate

  2011cites this paper
• Glucocorticoid-Induced Osteoporosis: Basic Pathological Mechanisms, Clinical Features, and Management in the New Millennium

  2011cites this paper
• Chapter 18, The Spectrum of Pediatric Osteoporosis

  2011cites this paper
• Principles of Supportive Care

  2011cites this paper
• Case studies of kyphoplasty and vertebroplasty integrated by anti-osteoporotic therapy.

  2011cites this paper
• [Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment].

  2011cites this paper
• Evaluation of Bone Fragility and Fracture Prevention

  2011cites this paper
• Effects of glucocorticoids on growth and bone mineralization.

  2011cites this paper
• A potential therapeutic approach to overload-induced bone loss around implant: parathyroid hormone (PTH).

  2011cites this paper
• Current indications for prevention and therapy of steroid-iduced osteoporosis in men and women.

  2011cites this paper
• [Current indications for prevention and therapy of steroid-induced osteoporosis in men and women].

  2011cites this paper
• Update on glucocorticoid-induced osteoporosis.

  2011cites this paper
• Effects of glucocorticoids on growth and bone mineralization Os glicocorticoides e seus efeitos no crescimento e na mineralização óssea

  2011cites this paper
• Teriparatide in the treatment of postmenopausal osteoporosis

  2010cites this paper
• Metabolic Bone Disease in Gastrointestinal Disorders

  2010cites this paper
• Role of teriparatide in treatment of glucocorticoid-induced osteoporosis

  2010influential citation
• Glucocorticoid induced osteoporosis

  2010cites this paper
• Osteoporosis y Metabolismo Mineral

  2010cites this paper
• Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis

  2010influential citation
• Review paper Bone metabolism disorders and glucocorticoid therapy in patients with pemphigus

  2010cites this paper
• Mechanical vibration preserves bone structure in rats treated with glucocorticoids.

  2010cites this paper
• Management of glucocorticoid-induced osteoporosis

  2010cites this paper
• Dietary dried plum increases bone mass in adult and aged male mice.

  2010cites this paper
• Glucocorticoids are not always deleterious for bone

  2010cites this paper
• 16. Metabolic Bone Disease in Gastrointestinal Disorders

  2010cites this paper
• Treatment of Cushing disease: overview and recent findings

  2010cites this paper
• Clinical Use of Parathyroid Hormone in Osteoporosis

  2010cites this paper
• 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

  2010cites this paper
• Osteoporosis induced by corticoids

  2010cites this paper
• Differential Maintenance of Cortical and Cancellous Bone Strength Following Discontinuation of Bone-Active Agents

  2010cites this paper
• Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease – a population‐based database study

  2010cites this paper
• Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men

  2010influential citation
• Emerging drugs for postmenopausal osteoporosis

  2009cites this paper
• Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)

  2009influential citation
• Management of glucocorticoids-induced osteoporosis: role of teriparatide

  2009cites this paper
• Management of glucocorticoids-induced osteoporosis: role of teriparatide

  2009cites this paper
• Bone density vs bone quality: What’s a clinician to do?

  2009cites this paper
• Nutritional and metabolic issues in solid organ transplantation: targets for future research.

  2009cites this paper
• IMPORTANCIA DE LA OSTEOPROTEGERINA EN LA ENFERMEDAD METABÓLICA ÓSEA Y LA ENFERMEDAD CARDIOVASCULAR DE PACIENTES CON DIABETES MELLITUS TIPO 2

  2009cites this paper
• Glucocorticoid-induced osteoporosis: treatment update and review

  2009cites this paper
• Is teriparatide or alendronate the best treatment for glucocorticoid-induced osteoporosis?

  2008cites this paper
• Clinical and Basic Aspects of Glucocorticoid Action in Bone

  2008cites this paper
• [Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine].

  2008cites this paper
• Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna

  2008cites this paper
• Parathyroid hormone treatment for osteoporosis

  2008cites this paper
• Bone-forming agents in the management of osteoporosis.

  2008cites this paper
• CHAPTER 80 – New Approaches to Osteoporosis Therapeutics

  2008cites this paper
• Pharmacological Mechanisms of Therapeutics: Parathyroid Hormone

  2008cites this paper
• Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window

  2008cites this paper
• Recent Advances in the Management of Steroid Induced Osteoporosis

  2008cites this paper
• CHAPTER 44 – Glucocorticoid-Induced Osteoporosis

  2008cites this paper
• CHAPTER 78 – Treatment with PTH Peptides

  2008cites this paper
• Teriparatide in the treatment of osteoporosis.

  2008cites this paper
• Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.

  2008cites this paper
• Twenty years of progress with parathyroid hormone (PTH): from specialized and "difficult" measurement to common laboratory parameter and treatment option in osteoporosis.

  2008cites this paper